Akk Medical Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases Research
At Akk Medical Sp. z o.o. in Gdansk, clinical trials in immune system diseases are focused on improving care for people with chronic inflammatory skin conditions. The research is centered on testing new therapies and assessing how well they reduce symptoms such as itching and inflammation.
- Prurigo nodularis studies exploring relief of severe itch and skin lesions
- Hidradenitis suppurativa research aimed at advancing treatment options for a difficult-to-manage condition
- Long-term safety evaluation of emerging treatments for chronic immune-mediated disease
This work reflects a strong interest in better symptom control, treatment effectiveness, and safety for patients living with persistent immune-mediated disorders.
Skin and Connective Tissue Diseases Research
Clinical research at this site also covers skin and connective tissue diseases, with a particular focus on conditions that can significantly affect comfort, appearance, and quality of life. The trials are designed to evaluate new medicines and compare them with placebo to see whether they improve visible skin changes and patient-reported symptoms.
- Plaque psoriasis trials assessing symptom improvement and overall skin clearance
- Vitiligo research supporting the search for better approaches to pigment-related skin disease
- Prurigo nodularis studies examining both itch control and lesion improvement
Across these studies, investigators are looking at treatment effectiveness and patient outcomes, helping advance options for chronic dermatologic conditions at the Centrum Medyczne Tu Się Leczy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Incyte Corp.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Akk Medical Sp. z o.o.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite) | Amgen Inc. | Phase III | Not Recruiting | Apr 2023 | Sep 2024 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rocatinlimab | 3 | Unknown | 2023-04-25 | 2024-11-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.